Portal de Periódicos da CAPES

TRANSFORMING GROWTH FACTOR-beta 1 (TGF-beta 1 ) IS SUFFICIENT TO INDUCE FIBROSIS OF RABBIT CORPUS CAVERNOSUM IN VIVO

1999; Lippincott Williams & Wilkins; Volume: 162; Issue: 3 Part 1 Linguagem: Inglês

10.1097/00005392-199909010-00089

1527-3792

Ajay Nehra, Matthew T. Gettman, Matthew A. Nugent, David G. Bostwick, David M. Barrett, Irwin Goldstein, Robert J. Krane, Robert B. Moreland,

Sexuality, Behavior, and Technology

No AccessJournal of UrologyInvestigative Urology1 Sep 1999TRANSFORMING GROWTH FACTOR-beta1 (TGF-beta1) IS SUFFICIENT TO INDUCE FIBROSIS OF RABBIT CORPUS CAVERNOSUM IN VIVO AJAY NEHRA, MATTHEW T. GETTMAN, MATTHEW NUGENT, DAVID G. BOSTWICK, DAVID M. BARRETT, IRWIN GOLDSTEIN, ROBERT J. KRANE, and ROBERT B. MORELAND AJAY NEHRAAJAY NEHRA , MATTHEW T. GETTMANMATTHEW T. GETTMAN , MATTHEW NUGENTMATTHEW NUGENT , DAVID G. BOSTWICKDAVID G. BOSTWICK , DAVID M. BARRETTDAVID M. BARRETT , IRWIN GOLDSTEINIRWIN GOLDSTEIN , ROBERT J. KRANEROBERT J. KRANE , and ROBERT B. MORELANDROBERT B. MORELAND View All Author Informationhttps://doi.org/10.1097/00005392-199909010-00089AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: The pleotropic cytokine TGF-beta1 which induces connective tissue synthesis, and inhibits the growth of smooth muscle cells, has been implicated in corpus cavernosum fibrosis. The objective of this study was to determine the dose and time dependence of TGF-beta1 as an active agent in penile corporal fibrosis in an animal model. Materials and Methods: A time release method of delivery was developed using sodium alginate microspheres containing recombinant human (rh) TGF-beta (1). New Zealand White rabbits were injected intracorporally with a single alginate microsphere either with or without rh-TGF-beta1. Dosage was varied from 325 to 1500 ng./bead. Animals were sacrificed at either three or five days post injection and the penises removed en bloc, examined, and processed for quantitative histomorphometric analysis, staining the sections with Masson's trichrome. Results: Alginate microspheres containing [(125) I]-rh-TGF-beta1 showed slow-release kinetics (t1/2 = 10.5 hours). Histomorphometric analysis of 60 sets of high powered fields/treatment/animal showed dose dependent decreases in percentage of corporal smooth muscle with TGF-beta1 treatment (750 to 1500 ng./bead). Placebo (alginate microspheres alone) had trabecular smooth muscle content comparable to values previously reported for untreated rabbit corpus cavernosum. Conclusions: This study confirms that TGF-beta1 induces fibrosis in situ by altering connective tissue synthesis and hence the structure of the corpus cavernosum. Injection of rh-TGF-beta1 impregnated alginate microspheres into the corpus cavernosum resulted in dose-dependent decreases in percentage of corporal smooth muscle. References 1 : The physiology of penile erection. Physiol. Rev.1995; 75: 191. Google Scholar 2 : Molecular biology of erectile function and dysfunction. Mol. Urol.1997; 1: 35. Google Scholar 3 : Is there a role of hypoxema in penile fibrosis?. Int. J. Impotence Res.1998; 10: 113. Google Scholar 4 : Correlation of altered penile ultrastructure with clinical arterial evaluation. J. Urol.1989; 142: 1462. Link, Google Scholar 5 : Clinical significance of ultrastructural findings in the corpus cavernosa of normal and impotent men. J. Urol.1990; 143: 289. Link, Google Scholar 6 : Ultrastructural changes in impotent penile tissue: a comparison of 65 patients. J. Urol.1991; 145: 749. Link, Google Scholar 7 : Computerized analysis of smooth muscle fibers in potent and impotent patients. J. Urol.1991; 146: 1015. Link, Google Scholar 8 : Collagen alterations in the corpus cavernosum of men with sexual dysfunction. J. Urol.1992; 148: 467. Link, Google Scholar 9 : Mechanisms of venous leak in erectile dysfunction in patients with vascular risks factors: a clinicopathologic correlation of corporal veno-occlusion. J. Urol.1996; 156: 1320. Link, Google Scholar 10 : Corporeal veno-occlusive dysfunction: predominantly intracavernous smooth muscle pathology. J. Urol.1997; 157: 1678. Link, Google Scholar 11 : Transforming growth factor-beta in disease: the dark side of tissue repair. J. Clin. Invest.1992; 90: 1. Google Scholar 12 : Transforming growth factor beta in tissue fibrosis. New Engl. J. Med.1994; 331: 1286. Google Scholar 13 : Beta-type transforming growth factor specifies organizational behavior in vascular smooth muscle cell cultures. J. Cell. Biol.1987; 105: 465. Google Scholar 14 : Coordinate regulation of transforming growth factor beta gene expression and cell proliferation in hamster lungs undergoing bleomycin-induced pulmonary fibrosis. J. Clin. Invest.1989; 84: 1836. Google Scholar 15 : Transforming growth factor beta1 and alpha in chronic liver disease. Effects of interferon alpha therapy. N. Engl. J. Med.1991; 324: 933. Google Scholar 16 : Expression of transforming growth factor-beta1 is increased in human vascular restenosis lesions. J. Clin. Invest.1992; 90: 1582. Google Scholar 17 : Structural heterogeneity of the diffuse intimal thickening and correlation with distribution of TGF-beta1. J. Vasc. Res.1993; 30: 293. Google Scholar 18 : PGE1 suppresses the induction of collagen synthesis by transforming growth factor-beta1 in human corpus cavernosum smooth muscle. J. Urol.1995; 153: 826. Link, Google Scholar 19 : Oxygen tension modulates transforming growth factor-beta1 expression and PGE production in human corpus cavernosum smooth muscle cells. Mol. Urol.1998; 2: 41. Google Scholar 20 : Oxygen tension regulates the nitric oxide pathway: Physiological role in penile erection. J. Clin. Invest.1993; 91: 437. Google Scholar 21 : Basic fibroblast growth factor enhances the coupling of intimal hyperplasia and proliferation of vasa vasorum in injured rat arteries. J. Clin. Invest.1992; 89: 465. Google Scholar 22 : Controlled release of fibroblast growth factor: activity in cell culture. Mater. Res. Soc. Symp. Proceed.1992; 252: 273. Google Scholar 23 : Cavernosal expandability is an erectile tissue mechanical property which predicts trabecular histology in an animal model of vasculogenic erectile dysfunction. J. Urol.1998; 159: 2229. Link, Google Scholar 24 : Hepatic processing of transforming growth factor beta in the rat. Uptake, metabolism and biliary excretion. J. Clin. Invest.1990; 80: 750. Google Scholar 25 : An in vivo model for transforming growth factor-beta1 induced corporal fibrosis: implications for penile ischemia-associated fibrosis. J. Urol.1996; 155: 622A. (Abstract 1243). Google Scholar 26 : Transforming growth factor beta. A biologic chorioretinal glue. Arch. Ophthalmol.1989; 107: 577. Google Scholar 27 : Cyclic AMP suppresses TGF-beta1-induced collagen synthesis in human corpus cavernosum smooth muscle cells. Int. J. Impotence Res.1999; . Google Scholar 28 : The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. J. Urol.1996; 155: 802. Link, Google Scholar 29 : Transforming growth factor-beta1 (TGF-beta (1)) in penile and prostate growth in the rat during sexual maturation. J. Androl.1998; 19: 50. Google Scholar 30 : Peyronie's disease is associated with an increase in transforming growth factor-beta protein expression. J. Urol.1997; 158: 1391. Link, Google Scholar 31 : An animal model of Peyronie's-like condition associated with an increase in transforming growth factor-beta mRNA and protein expression. J. Urol.1997; 158: 2284. Link, Google Scholar 32 : Histological and ultrastructural alterations in an animal model of Peyronie's disease. Br. J. Urol.1998; 81: 445. Google Scholar 33 : An organ culture model system for the study of collagen synthesis in corpus cavernosum in situ. Int. J. Impotence Res.1998; 10: 77. Google Scholar 34 : Elevated levels of plasma transforming growth factor-beta in patients with hepatocellular carcinoma. Jap. J. Cancer Res.1992; 83: 676. Google Scholar 35 : Transforming growth factor-beta 1 circulates in normal plasma and is unchanged in advanced metastatic breast cancer. Clin. Cancer Res.1995; 1: 129. Google Scholar 36 : Increased transforming growth factor beta 1 plasma levels in patients with renal cell carcinoma: a tumor-specific marker?. Urol. Int.1998; 60: 205. Google Scholar 37 : Latent transforming growth factor-beta: structural features and mechanisms of activation. Kidney Int.1997; 51: 1376. Google Scholar 38 : Characterization of latent transforming growth factor-beta from human seminal plasma. Am. J. Reprod. Immunol.1995; 33: 282. Google Scholar 39 : Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc. Natl. Acad. Sci. USA1986; 83: 4167. Google Scholar 40 : Accelerated healing of incisional wounds in rats induced by transforming growth factor-beta. Science1987; 237: 1333. Google Scholar 41 : Transforming growth factor-beta stimulates wound healing and modulates extracellular matrix gene expression in pig skin incisional wound model. J. Invest. Dermatol.1991; 97: 34. Google Scholar 42 : Effect of topical recombinant TGF-beta on healing of partial thickness injuries. J. Surg. Res.1991; 51: 344. Google Scholar 43 : Recombinant human transforming growth factor-beta 1 (rhTGF-beta 1) enhances healing and strength of granulation skin wounds. Growth Factors1990; 3: 267. Google Scholar 44 : Accelerated healing of ulcer wounds in the rabbit ear by recombinant human transforming growth factor-beta 1. Growth Factors1990; 2: 273. Google Scholar 45 : Direct transfer of transforming growth factor beta 1 gene into arteries stimulates fibrocellular hyperplasia. Proc. Natl. Acad. Sci. USA1993; 90: 10759. Google Scholar From the Departments of Urology, Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, and the Departments of Urology, Ophthalmology and Biochemistry, Boston University School of Medicine, Boston, Massachusetts(Nehra) Requests for reprints: Department of Urology, Mayo Clinic, Mayo E17, 200 First Street S.W., Rochester, MN 55905.Supported by National Institutes of Health grants DK39080, DK40025 and DK 47950 and a grant from the Mayo Clinic and Foundation.© 1999 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited bySIROKY M and AZADZOI K (2018) Vasculogenic Erectile Dysfunction: Newer Therapeutic StrategiesJournal of Urology, VOL. 170, NO. 2S, (S24-S30), Online publication date: 1-Aug-2003.Monga M, Cosgrove D, Zupkas P, Jain A, Kasyan A, Wilkes N and Rajasekaran M (2018) Small Intestinal Submucosa As A Tunica Albuginea Graft MaterialJournal of Urology, VOL. 168, NO. 3, (1215-1221), Online publication date: 1-Sep-2002.SIMOPOULOS D, GIBBONS S, MALYSZ J, SZURSZEWSKI J, FARRUGIA G, RITMAN E, MORELAND R and NEHRA A (2018) CORPOREAL STRUCTURAL AND VASCULAR MICRO ARCHITECTURE WITH X-RAY MICRO COMPUTERIZED TOMOGRAPHY IN NORMAL AND DIABETIC RABBITS: HISTOPATHOLOGICAL CORRELATIONJournal of Urology, VOL. 165, NO. 5, (1776-1782), Online publication date: 1-May-2001. Volume 162Issue 3 Part 1September 1999Page: 910-915 Advertisement Copyright & Permissions© 1999 by American Urological Association, Inc.MetricsAuthor Information AJAY NEHRA More articles by this author MATTHEW T. GETTMAN More articles by this author MATTHEW NUGENT More articles by this author DAVID G. BOSTWICK More articles by this author DAVID M. BARRETT More articles by this author IRWIN GOLDSTEIN More articles by this author ROBERT J. KRANE More articles by this author ROBERT B. MORELAND More articles by this author Expand All Advertisement PDF downloadLoading ...